Literature DB >> 31644952

Crosstalk between Nrf2 signaling and mitochondrial function in Parkinson's disease.

Navneet Ammal Kaidery1, Manuj Ahuja1, Bobby Thomas2.   

Abstract

Search for a definitive cure for neurodegenerative disorders like Parkinson's disease (PD) has met with little success. Mitochondrial dysfunction and elevated oxidative stress precede characteristic loss of dopamine-producing neurons from the midbrain in PD. The majority of PD cases are classified as sporadic (sPD) with an unknown etiology, whereas mutations in a handful of genes cause monogenic form called familial (fPD). Both sPD and fPD is characterized by proteinopathy and mitochondrial dysfunction leading to increased oxidative stress. These pathophysiological mechanisms create a vicious cycle feeding into each other, ultimately tipping the neurons to its demise. Effect of iron accumulation and dopamine oxidation adds an additional dimension to mitochondrial oxidative stress and apoptotic pathways affected. Nrf2 is a redox-sensitive transcription factor which regulates basal as well as inducible expression of antioxidant enzymes and proteins involved in xenobiotic detoxification. Recent advances, however, shows a multifaceted role for Nrf2 in the regulation of genes connected with inflammatory response, metabolic pathways, protein homeostasis, iron management, and mitochondrial bioenergetics. Here we review the role of mitochondria and oxidative stress in the PD etiology and the potential crosstalk between Nrf2 signaling and mitochondrial function in PD. We also make a case for the development of therapeutics that safely activates Nrf2 pathway in halting the progression of neurodegeneration in PD patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ferroptosis; Metabolomics; Mitochondria; Neurodegeneration; Nrf2; Parkinson's disease

Mesh:

Substances:

Year:  2019        PMID: 31644952      PMCID: PMC6981291          DOI: 10.1016/j.mcn.2019.103413

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  155 in total

1.  α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons.

Authors:  Richard Ortega; Asuncion Carmona; Stéphane Roudeau; Laura Perrin; Tanja Dučić; Eleonora Carboni; Sylvain Bohic; Peter Cloetens; Paul Lingor
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

2.  Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis.

Authors:  Ling-Chu Chang; Shih-Kai Chiang; Shuen-Ei Chen; Yung-Luen Yu; Ruey-Hwang Chou; Wei-Chao Chang
Journal:  Cancer Lett       Date:  2017-12-20       Impact factor: 8.679

3.  Lipid peroxidation as cause of nigral cell death in Parkinson's disease.

Authors:  D Dexter; C Carter; F Agid; Y Agid; A J Lees; P Jenner; C D Marsden
Journal:  Lancet       Date:  1986-09-13       Impact factor: 79.321

4.  Nitric oxide activates an Nrf2/sulfiredoxin antioxidant pathway in macrophages.

Authors:  Kahina Abbas; Jacques Breton; Anne-Gaelle Planson; Cécile Bouton; Jérome Bignon; Cendrine Seguin; Sylvie Riquier; Michel B Toledano; Jean-Claude Drapier
Journal:  Free Radic Biol Med       Date:  2011-04-03       Impact factor: 7.376

5.  Nrf2 mitigates LRRK2- and α-synuclein-induced neurodegeneration by modulating proteostasis.

Authors:  Gaia Skibinski; Vicky Hwang; Dale Michael Ando; Aaron Daub; Alicia K Lee; Abinaya Ravisankar; Sara Modan; Mariel M Finucane; Benjamin A Shaby; Steven Finkbeiner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-27       Impact factor: 11.205

6.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.

Authors:  A Yoritaka; N Hattori; K Uchida; M Tanaka; E R Stadtman; Y Mizuno
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

7.  NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson's disease.

Authors:  Anthony L Cook; Alejandra M Vitale; Sugandha Ravishankar; Nicholas Matigian; Greg T Sutherland; Jiangou Shan; Ratneswary Sutharsan; Chris Perry; Peter A Silburn; George D Mellick; Murray L Whitelaw; Christine A Wells; Alan Mackay-Sim; Stephen A Wood
Journal:  PLoS One       Date:  2011-07-01       Impact factor: 3.240

8.  THE METABOLISM OF TUMORS IN THE BODY.

Authors:  O Warburg; F Wind; E Negelein
Journal:  J Gen Physiol       Date:  1927-03-07       Impact factor: 4.086

Review 9.  PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson's Disease Pathobiology?

Authors:  Dominika Truban; Xu Hou; Thomas R Caulfield; Fabienne C Fiesel; Wolfdieter Springer
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

10.  Deficiency of Parkinson's disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation.

Authors:  Marta Delgado-Camprubi; Noemi Esteras; Marc Pm Soutar; Helene Plun-Favreau; Andrey Y Abramov
Journal:  Cell Death Differ       Date:  2016-09-30       Impact factor: 15.828

View more
  14 in total

1.  A pantothenate kinase-deficient mouse model reveals a gene expression program associated with brain coenzyme a reduction.

Authors:  Chitra Subramanian; Jiangwei Yao; Matthew W Frank; Charles O Rock; Suzanne Jackowski
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-01-07       Impact factor: 5.187

2.  Neuroprotective effects of Fomes officinalis Ames polysaccharides on Aβ25-35-induced cytotoxicity in PC12 cells through suppression of mitochondria-mediated apoptotic pathway.

Authors:  Ayijiang Habaike; Mirensha Yakufu; Yuanyuan Cong; Yimin Gahafu; Zhen Li; Palida Abulizi
Journal:  Cytotechnology       Date:  2020-05-20       Impact factor: 2.058

3.  NaSH increases SIRT1 activity and autophagy flux through sulfhydration to protect SH-SY5Y cells induced by MPP~.

Authors:  Jing Li; Mei Li; Cui Wang; Shuhu Zhang; Qiang Gao; Liping Wang; Lan Ma
Journal:  Cell Cycle       Date:  2020-08-13       Impact factor: 4.534

4.  Application of flavonoids for the protection of nigral dopaminergic neurons from oxidative stress.

Authors:  Sang Ryong Kim
Journal:  Neural Regen Res       Date:  2021-07       Impact factor: 5.135

5.  Brain Hepcidin Suppresses Major Pathologies in Experimental Parkinsonism.

Authors:  Tuo Liang; Zhong-Ming Qian; Ming-Dao Mu; Wing-Ho Yung; Ya Ke
Journal:  iScience       Date:  2020-06-19

Review 6.  Ferroptosis Mechanisms Involved in Neurodegenerative Diseases.

Authors:  Cadiele Oliana Reichert; Fábio Alessandro de Freitas; Juliana Sampaio-Silva; Leonardo Rokita-Rosa; Priscila de Lima Barros; Debora Levy; Sérgio Paulo Bydlowski
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

7.  Bach1 derepression is neuroprotective in a mouse model of Parkinson's disease.

Authors:  Manuj Ahuja; Navneet Ammal Kaidery; Otis C Attucks; Erin McDade; Dmitry M Hushpulian; Arsen Gaisin; Irina Gaisina; Young Hoon Ahn; Sergey Nikulin; Andrey Poloznikov; Irina Gazaryan; Masayuki Yamamoto; Mitsuyo Matsumoto; Kazuhiko Igarashi; Sudarshana M Sharma; Bobby Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-09       Impact factor: 11.205

8.  Long non-coding RNA myocardial infarction-associated transcript promotes 1-Methyl-4-phenylpyridinium ion-induced neuronal inflammation and oxidative stress in Parkinson's disease through regulating microRNA-221-3p/ transforming growth factor /nuclear factor E2-related factor 2 axis.

Authors:  Yue Lang; Hui Zhang; Haojia Yu; Yu Li; Xiao Liu; Minjie Li
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

Review 9.  Homocysteine and Mitochondria in Cardiovascular and Cerebrovascular Systems.

Authors:  Peter Kaplan; Zuzana Tatarkova; Monika Kmetova Sivonova; Peter Racay; Jan Lehotsky
Journal:  Int J Mol Sci       Date:  2020-10-18       Impact factor: 5.923

Review 10.  PGC-1α protects from myocardial ischaemia-reperfusion injury by regulating mitonuclear communication.

Authors:  Yan-Qing Li; Yan Jiao; Ya-Nan Liu; Jia-Ying Fu; Lian-Kun Sun; Jing Su
Journal:  J Cell Mol Med       Date:  2021-01-19       Impact factor: 5.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.